

Linda D. Bosserman

MD · PhD · AASECT · FACP · FASCO

Professor, City of Hope National Medical Center
Founder & Medical Director, CHOICES

3803 Seashore Drive, Newport Beach, CA 92663

Cell 909 921 7492

lbosserman@coh.org · Linda@DrBosserman.com

linda.bosserman1@gmail.com

45 yrs IN MEDICINE & ONCOLOGY	64 PEER-REVIEWED ARTICLES	117 INVITED LECTURES	ASCO JCO OP EDITOR-IN-CHIEF
-------------------------------------	---------------------------------	-------------------------	--------------------------------

EDUCATION

PhD, Clinical Sexology – Modern Sex Therapy Institute	2021–2024
Focus: Sexuality Issues in Cancer Patients · AASECT Certified Sex Counselor, March 2024	
M.D. – Stanford University School of Medicine	1981
A.B. Biochemistry, with Highest Honors – University of California, Berkeley	1977

POSTGRADUATE TRAINING

Fellowship, Medical Oncology – Dana-Farber Cancer Institute, Boston, MA	1985–1988
Internship & Residency, Internal Medicine – Stanford University Hospital	1981–1984

BOARD CERTIFICATIONS & LICENSURE

AASECT Certified Sex Counselor	March 2024
Diplomate, ABIM – Subspecialty of Medical Oncology	1989
Diplomate, American Board of Internal Medicine	1984
Diplomate, National Board of Examiners	1982
California Medical License #G49004 – Active	Licensed 1982
NPI 1346289824	

ACADEMIC APPOINTMENTS

Professor, Medical Oncology and Therapeutic Research – City of Hope	2021–Present
Clinical Professor, Medical Oncology – City of Hope Medical Foundation	2020–2021

Clinical Assistant Professor, Medical Oncology – City of Hope Medical Foundation	2014–2020
Attending Physician, Oncology – Loma Linda University Medical Center	1994–1997
Clinical Instructor, Medicine – Dana-Farber Cancer Institute, Harvard Medical School	1988–1989
Clinical Instructor, Internal & Emergency Medicine – Stanford University School of Medicine	1984

PROFESSIONAL EXPERIENCE

Founder & Medical Director, CHOICES	Jan 2026–Present
Cancer therapies and Hormone Options for Informed Care and Evidence-based Shared decision-making — an independent educational initiative for clinicians and patients, separate from her clinical role at City of Hope · DrBosserman.com · @DrBosserman on Substack, Facebook, TikTok, Instagram & LinkedIn	
Medical Oncologist & Breast Cancer Specialist; Sexual Health, Menopause & Andropause Care for Patients with Cancer	2024–Present
City of Hope National Medical Center, Newport Beach, CA	
Medical Director, Enterprise Pathways & Protocols Program – City of Hope Enterprise	2024–Present
City of Hope National Medical Center, Duarte, CA	
Medical Director, Value-Based Cancer Care & Center for International Medicine	2020–Present
City of Hope National Medical Center, Duarte, CA	
Editor in Chief, JCO Oncology Practice (<i>formerly Journal of Oncology Practice</i>)	2019–2022
American Society of Clinical Oncology, Alexandria, VA — selected after competitive national search; confirmed by ASCO Board of Directors	
Medical Advisor, Value-Based Cancer Care, Pathways & Epic EHR Implementation	2017–2020
City of Hope Medical Foundation, Duarte, CA	
Medical Oncologist, Breast & Gynecologic Cancer Specialist	2014–2020
City of Hope Medical Foundation, Upland & Rancho Cucamonga, CA	
Medical Director, California – US Oncology / McKesson Specialty Health	2010–2014
Chief Medical Officer / Chief Quality Officer – Cancer Clinics of Excellence (CCE)	2007–2009

President, Managing Partner & Medical Oncologist – Wilshire Oncology Medical Group, Inc.	2003–2014
Breast & Gynecologic Cancer Specialist · La Verne & Upland, CA	
Medical Oncologist, Breast & Adult Cancer Specialist – Wilshire Oncology Medical Group, Rancho Cucamonga, CA	1990–2003
Medical Director, Robert & Beverly Lewis Family Cancer Care Center – Pomona, CA	2000–2003
Medical Oncologist & Hematologist – Goddard Medical Group, Brockton, MA	1988–1989
Founded the first Medical Oncology / Hematology specialty service in southern Massachusetts	

NATIONAL LEADERSHIP & ORGANIZATIONAL ROLES

AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)	
Member, Conquer Cancer Foundation Nominating Committee (4- year term)	2019–Present
Member, CancerLinq Physician Advisory Committee	2019–Present
Advisor, JCO Oncology Practice Fellow Program	2019–2022
Symposia Chair / Co-Chair, ASCO Oncology Practice Symposia	2017–2019
Policy Advisor, ASCO Policy Fellows	2017–2018
Fellow, ASCO (FASCO)	2017
Member, Provider Payment Reform Task Force	2016–2022
Founding Member, TAPUR Study Steering Committee	2015–2019
Member, Board of Directors · Liaison Member, Clinical Practice Committee	2014–2018
Founding Member & Author, Sentinel Lymph Node Biopsy Guideline Committee	2009–2021
Founding Member & Author, Bisphosphonate / Bone Metastasis Guideline Committee	1997–2022
Member, Public Issues Committee	1997–2004
PATHWAYS & INFORMATICS BOARDS	
Co-Chair (2019–2023) & Member, Elsevier ClinPath Breast Cancer Pathway Committee	2017–Present
Elected Member, Epic Adult Oncology Steering Advisory Board (4 terms)	2018–Present
COMMUNITY ONCOLOGY & OTHER NATIONAL ORGANIZATIONS	
Member, International Society for Study of Women's Sexual Health (ISSWSH)	2023–Present

Member, Menopause Society (formerly NAMS)	2022–Present
Member, AASECT – American Association of Sex Educators, Counselors & Therapists	2021–Present
Member, Scientific Advisory Committee – CI4CC (Clinical Informatics 4 Cancer Centers)	2017–Present
Founding Member, Scientific Advisory Committee – Value in Cancer Care Consortium (Vi3C)	2017–2021
Steering Committee Member, National Cancer Center Business Summit (ASCO liaison)	2007–2022
Board of Directors & Executive Committee · Co-Chair, Clinical Quality Committee – CCE	2005–2009
Chair, Quality, Safety & P4P Committee – Community Oncology Alliance (COA)	2005–2007
Founding Member & Secretary, Board of Directors – COA	2003–2008
Fellow, American College of Physicians (FACP)	1997
Member, American Society of Clinical Oncology	1988–Present

REGIONAL & INSTITUTIONAL LEADERSHIP

Medical Lead, Sexual Health in Patients with Cancer – City of Hope NMC	2023–Present
Member / Chair, Promotion Committees – Dept. of Medical Oncology, City of Hope	2020–Present
Breast Cancer Tumor Board Member – City of Hope NMC	2014–Present
Board of Directors – Los Angeles County Fairplex (non-profit, \$80M enterprise)	2016–Present
Physician Wellness Committee Member – City of Hope	2017–2021
Invited Participant, White House Physician Forum on Health Reform	2009
Board of Directors – San Antonio Regional Hospital Foundation	2008–2016
Medical Director, Breast Health Program – San Antonio Regional Hospital	2000–2016
Cancer Committee & Tumor Board Member – San Antonio Regional Hospital	1990–2016
Board of Directors, California Division – American Cancer Society	1999–2003
Director, Comprehensive Breast Program & Psycho-Social Oncology – Lewis Cancer Care Center	1996–2002
Cancer Committee & Tumor Board Member – Pomona Valley Hospital Medical Center	1991–2011
Founding President, American Cancer Society – Inland Valley Unit	1992–1995
Founding President, Wellness Community – Inland Valley Division	1992–1993

**SELECTED HONORS
& AWARDS**

Best Doctor in Breast Cancer – Best Doctors in America	2005–2023
Inland Empire Best Doctors – Inland Empire Magazine	2013–2018
Woman of Distinction – 63rd Assembly District of California	2011
US News Top Doctor – US News & World Report	2011
Top Oncologist, Rancho Cucamonga – International Association of Oncologists	2011
Humanitarian of the Year – LeRoy Haynes Center for Children & Family Services	2005
Highest Clinical Trial Accrual of Year – Wilshire Oncology Medical Group	2005
Doctors Who Make a Difference – Inland Empire Magazine	2004
Woman of Distinction – Soroptimist International, Inland Valley Chapter	1997
Humanitarian of the Year – Inland Hospice Association	1993
Pride in Medicine Nurse/Physician Quality Award – Massachusetts Medical Society	1989
Regent's Scholar – University of California, Berkeley	1973–1977

**EDITORSHIPS &
EDITORIAL BOARDS**

Editor in Chief, JCO Oncology Practice (<i>formerly Journal of Oncology Practice</i>) – ASCO	2019–2022
Consulting Editor, Journal of Oncology Practice – ASCO	2021–2022
Invited Reviewer, Journal of Oncology Practice	2013–Present
Editor, Journal of Clinical and Supportive Oncology (<i>formerly Community Oncology</i>)	2004–2018
Editorial Board Member, ONCOLOGY	1999–2017

**GRANTS &
RESEARCH SUPPORT**

Natural Killer Cell Function Research Fellowship – National Cancer Center	1987–1988
Principal Investigator · \$25,000 peer-reviewed competitive grant · Advisor: Dr. Jerome Ritz	
Fellowship Stipend – Friends of the Dana-Farber Cancer Institute	1986
\$35,000	
Student Research Project – American Cancer Society	1981
Patient Outcomes, Head & Neck Clinic, Stanford University Medical Center · PI: Dr. Charlotte Jacobs	

PUBLICATIONS**PEER-REVIEWED ARTICLES**

- Bosserman LD**, Dizon DS. Menopause Hormone Therapy after Breast Cancer: Personalization not Prohibition. *Journal of Clinical Oncology*. March 31, 2026.
- Bosserman LD**, Lin YH, Shayani S, Moore B, Morse D. Teams, Tools, Processes and Resources to Manage Oncologic Clinical Decision Support: Lessons Learned from City of Hope's Multistate, Academic, and Community Oncology Enterprise. *Journal of Clinical Medicine*. 14(6):1963, 2025.
- Wong MH, Jones VC, Yu W, **Bosserman LD**, Lavasani SM, Patel N, Sedrak M, Stewart D, Waisman J, Yuan Y, Mortimer JE. UGT1A1*28 Polymorphism and the Risk of Toxicity and Disease Progression in Patients with Breast Cancer Receiving Sacituzumab Govitecan. *Cancer Medicine*. 13(15):e70004, 2024.
- Taparra KA, Benavente R, Shih J, **Bosserman LD**, Chino F, Patel M, Shah C, et al. Race/Ethnicity Representation in Phase 2/3 Oncology Clinical Trial Publications in the United States. *Submitted JCO*, 2023.
- Bosserman LD**, Mambetsariev I, Ladbury C, et al. Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes. *Journal of Clinical Medicine*. 11(22):6738, 2022.
- Zachariah F, Rossi L, Roberts L, **Bosserman L**. Prospective Comparison of Medical Oncologists and a Machine Learning Model to Predict 3-Month Mortality. *JAMA Network Open*. 5(5):e2214514, 2022.
- Lee J, Yost S, Chi Y, **Bosserman L**, et al. Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancers. *Cancers*. 14(13):3159, 2022.
- Thomas C, Hirschorn A, Tomkins J, **Bosserman L**, et al. New Landscape: Physician Compensation. *JCO Oncology Practice*. 17(4):186-189, 2021.
- Bosserman L**, Cianfrocca M, Yuh B, et al. Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: The City of Hope Experience. *Journal of Clinical Medicine*. 10(2):188, 2021.
- Cinar P, Cox J, Kamal A, **Bosserman L**. Oncology Care Delivery in the COVID-19 Pandemic: An Opportunity to Study Innovations. *JCO Oncology Practice*. 16(8):431-434, 2020.
- Liu J, Gutierrez E, Tiwari A, **Bosserman LD**, et al. Strategies to Improve Participation of Older Adults in Cancer Research. *Journal of Clinical Medicine*. 9(5):1571, 2020.
- Hurvitz S, Caswell-Jin J, McNamara K, **Bosserman L**, et al. Pathologic and molecular responses from a phase II randomized trial of neoadjuvant trastuzumab and/or lapatinib in HER2-positive breast cancer (TRIO-US B07). *Nature Communications*. 11(1):1-15, 2020.
- Hlubocky F, Taylor L, Marron J, **Bosserman L**, et al. A Call to Action: Ethics Committee Recommendations for Addressing Burnout and Moral Distress in Oncology. *JCO Oncology Practice*. 16(4):191-199, 2020.
- Pan K, **Bosserman L**, Chlebowski R. Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *Journal of Clinical Oncology*. 37(11):858-861, 2019. (with Reply, 37(21):1840-1841, 2019.)
- Rugo H, Palma J, Tripathy D, **Bosserman L**.* Characterization, management, and future considerations for ErbB-family TKI-associated diarrhea. *Breast Cancer Research and Treatment*. 175(1):5-15, 2019.
- Daly B, Zon RT, **Bosserman LD**.* Oncology Clinical Pathways: Charting the Landscape of Pathway Providers. *Journal of Oncology Practice*. 14(3):193-198, 2018.

- Van Poznak C, Somerfield MR, **Bosserman LD**, et al. Role of Bone Modifying Agents in Metastatic Breast Cancer: ASCO-CCO Focused Guideline Update. *Journal of Clinical Oncology*. 35(35):3978-3986, 2017.
- Yardley DA, Arrowsmith ER, **Bosserman LD**, et al. TITAN: Phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. *Breast Cancer Research and Treatment*. 164(3):649-658, 2017.
- Brooks GA,* **Bosserman LD**,* Mambetsariev I, Salgia R. Value-based Medicine and Integration of Tumor Biology. *ASCO Education Book*. 37:833-840, 2017.
- Zon RT, Edge SB, Page RD, **Bosserman LD**.* ASCO Criteria for High-Quality Clinical Pathways in Oncology. *Journal of Oncology Practice*. 13(3):207-210, 2017.
- Lyman GH, Somerfield MR, **Bosserman LD**, et al. Sentinel Lymph Node Biopsy for Early-Stage Breast Cancer: ASCO Clinical Practice Guideline Update. *Journal of Clinical Oncology*. 35(5):561-564, 2017.
- Zon RT, Frame JN, Neuss MN, **Bosserman LD**.* ASCO Policy Statement on Clinical Pathways in Oncology. *Journal of Oncology Practice*. 12(3):261-266, 2016.
- Yardley DA, **Bosserman LD**, O'Shaughnessy JA, et al. Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for metastatic HER2-negative breast cancer. *Breast Cancer Research and Treatment*. 154(1):89-97, 2015.
- Landercasper J, Attai D, **Bosserman L**, et al. Toolbox to Reduce Lumpectomy Reoperations. *Annals of Surgical Oncology*. 22(10):3174-3183, 2015.
- Bosserman L**, Rogers K, Willis C, Davidson D, et al. Application of a Drug-Induced Apoptosis Assay to Identify Treatment Strategies in Recurrent or Metastatic Breast Cancer. *PLOS ONE*. 10(5):e0122609, 2015.
- Yardley DA, Kaufman PA, **Bosserman L**, et al. Quantitative measurement of HER2 expression in breast cancers: correlation with overall survival. *Breast Cancer Research*. 17(1):41, 2015.
- Awan FT, Hillmen P, **Bosserman LD**, et al. LUCID trial: lumiliximab in combination with FCR versus FCR alone in relapsed chronic lymphocytic leukaemia. *British Journal of Haematology*. 167(4):466-477, 2014.
- Lyman GH, Temin S, Edge SB, Newman LA, **Bosserman LD**, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: ASCO clinical practice guideline update. *Journal of Clinical Oncology*. 32(13):1365-1383, 2014.
- Hurvitz SA, **Bosserman LD**, Chan D, et al. Cardiac safety results from a phase II study of two docetaxel-based regimens plus bevacizumab for adjuvant breast cancer. *SpringerPlus*. 3:244, 2014.
- Vahda LT, Vrdoljak E, Gómez H, **Bosserman L**, et al. Efficacy and safety of ixabepilone plus capecitabine in elderly patients with metastatic breast cancer. *Journal of Geriatric Oncology*. 4(4):346-352, 2013.
- Krzyzanowska MK, Blayney DW, **Bosserman LD**, Sullivan TJ. Models that work: Incorporating quality principles in different clinical settings. *Journal of Oncology Practice*. 9(3):135-137, 2013.
- Yardley DA, Hart L, **Bosserman L**, et al. Phase II study of lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer. *Breast Cancer Research and Treatment*. 137(2):457-464, 2013.

- Bosserman L**, Prendergast F, Herbst R, Fleisher M. The microculture-kinetic (MiCK) assay in drug development and clinical care. *Cancer Research*. 72(16):3901-3905, 2012.
- Kleinman L, Benjamin K, **Bosserman L**, et al. The Anemia Impact Measure (AIM): a patient-reported outcome measure. *Quality of Life Research*. 21(7):255-266, 2012.
- Bosserman LD**, Verrilli D, McNatt W. Partnering with a Payer to Develop a Value-Based Medical Home Pilot. *Journal of Oncology Practice*. 18(4):SP189-190, 2012.
- Bosserman LD**, Rajurkar SP, Rogers K, Davidson DC, et al. Correlation of Drug-induced Apoptosis Assay Results with Oncologist Treatment Decisions. *Cancer*. 118(19):4877-4883, 2012.
- Valero V, Vrdolja E, Xu B, **Bosserman L**, et al. Maintenance of Clinical Efficacy Following Dose Reduction of Ixabepilone Plus Capecitabine. *Clinical Breast Cancer*. 12(4):240-246, 2012.
- Brufsky AM, Harker WG, Beck JT, **Bosserman L**, et al. Final 5-year results of Z-FAST trial. *Cancer*. 118(5):1192-1220, 2012.
- Rajurkar SP, Presant CA, **Bosserman LD**, McNatt WJ. A Copay Foundation Assistance Support Program for IV Cancer Therapy. *Journal of Oncology Practice*. 7(2):100-102, 2011.
- Poznak CV, Temin S, Yee G, Janjan N, **Bosserman L**, et al. ASCO Clinical Practice Guideline Update: Bone Modifying Agents in Metastatic Breast Cancer. *Journal of Clinical Oncology*. 29(9):1221-1227, 2011.
- Presant CA, **Bosserman L**, McNatt W, Emilio B. Implementing EHRs in Community Oncology Practices. *Oncology*. 25(1):19-20, 2011.
- Bosserman LD**, Vanderpool T, Bassi N, et al. A community oncology quality initiative: guideline adherence with adjuvant hormonal therapy in breast cancer. *Community Oncology*. 6(12):551-557, 2009.
- Fizazi K, **Bosserman L**, Gao G, et al. Denosumab Treatment of Prostate Cancer With Bone Metastases. *Journal of Urology*. 182(2):509-515, 2009.
- Brufsky AM, **Bosserman LD**, Caradonna RR, et al. Zoledronic Acid Prevents Aromatase Inhibitor-Associated Bone Loss: Z-FAST 36-Month Follow-Up. *Clinical Breast Cancer*. 9(2):77-85, 2009.
- Britten CD, Finn RS, **Bosserman LD**, et al. Phase I/II Trial of Trastuzumab plus Erlotinib in Metastatic HER2-Positive Breast Cancer. *Clinical Breast Cancer*. 9(1):16-22, 2009.
- Bosserman LD*** Genetic testing and management of BRCA1/2-positive breast and ovarian cancers. *Community Oncology*. Suppl 1(5):2-7, 2008.
- Bosserman LD**, Smith JA, Hellerstedt B, Geier L. Hereditary Cancer testing in community oncology practices. *Community Oncology*. Suppl 11:2-8, 2007.
- Presant CA, **Bosserman L**, Young T, et al. Aromatase inhibitor-associated arthralgia and/or bone pain. *Clinical Breast Cancer*. 7(10):775-778, 2007.
- Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, **Bosserman L**, et al. Efficacy and Safety of Ixabepilone in Advanced Breast Cancer. *Journal of Clinical Oncology*. 25(23):3407-3414, 2007.
- Glaspy J, Vadhan-Raj S, Patel R, **Bosserman L**, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa. *Journal of Clinical Oncology*. 24(15):2290-2307, 2006.

- Elting L, Fortner B, **Bosserman L**, Schwartzberg L. CMS demonstration project on quality of care. *Journal of Supportive Oncology*. 4(3):147-151, 2006.
- Martel CL, Presant CA, Ebrahimi B, **Bosserman LD**, et al. Bevacizumab-related toxicities: association of hypertension and proteinuria. *Community Oncology*. 3:90-93, 2006.
- Gitlitz BJ, Baker C, Chapman Y, Allen HJ, **Bosserman LD**, et al. A phase II study of gemcitabine and docetaxel in advanced urothelial carcinoma. *Cancer*. 98(9):1863-1869, 2003.
- Gregory SA, Case DC, **Bosserman L**, et al. Fourteen-Day CHOP Supported with G-CSF in Aggressive Non-Hodgkin's Lymphoma. *Clinical Lymphoma*. 4(2):93-98, 2003.
- Emmanouilides C, Rosen P, Telatar M, Malone R, **Bosserman L**, et al. Excellent Tolerance of Rituximab When Given after Mitoxantrone/Cyclophosphamide. *Clinical Lymphoma*. 1(2):146-151, 2000.
- Lynch P, Severin M, Mills A, **Bosserman L**, et al. Medical/Legal issues in genetic testing. *Cancer*. 80(S3):630-631, 1997.
- Boling EP, Primavera C, Friedmann G, King M, **Bosserman L**, et al. Non-invasive measurements of bone mass in adult renal osteodystrophy. *Bone*. 14(3):409-413, 1993.
- Robertson MJ, Socinski MA, Soiffer RJ, et al. Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation. *Bone Marrow Transplantation*. 8(2):143-145, 1991.
- Soiffer RJ, Mauch P, Tarbell NJ, et al. Total lymphoid irradiation to prevent graft rejection in HLA non-identical T cell-depleted allogeneic marrow. *Bone Marrow Transplant*. 7(1):23-33, 1991.
- Licht JD, **Bosserman LD**, Andersen JW, et al. Treatment of Low and Intermediate Grade Lymphoma With Intensive Combination Chemotherapy. *Cancer*. 66(4):632-639, 1990.
- Soiffer RJ, **Bosserman L**, Murray C, et al. Reconstitution of T Cell Function After CD6 Depleted Allogeneic Bone Marrow Transplantation. *Blood*. 75(10):2076-2084, 1990.
- Bosserman LD**, Murray C, Takvorian T, Anderson KC, et al. Mechanism of Graft Failure in HLA-Matched and HLA-Mismatched Bone Marrow Transplant Recipients. *Bone Marrow Transplant*. 4(3):239-245, 1989.

REVIEWS **4**

- Bosserman LD**, Henderson CI. Cancer in America, 2004. *Community Oncology*. 1:30-35, 2004.
- Bosserman LD**, Fitzgerald P. Malignant Paraganglioma. *Community Oncology*. 1(1):47-52, 2004.
- Bosserman LD**, Canellos GP. Recent advances in the treatment of Non-Hodgkin's Lymphoma. *Hospital Physician*. 23:77-90, 1987.
- Bosserman LD**, Ritz J. Treatment of Leukemia with Bone Marrow Transplant. *Current Concepts in Oncology*. 3:716, 1987.

BOOK CHAPTERS **1**

- Brooks G,* **Bosserman L**,* Salgia R. Value-Based Medicine and Integration of Tumor Biology. *ASCO Education Book*. June 2017. DOI: 10.14694/EDBK_175519.

- Bosserman L**, Duma N, Villalona-Calero M, et al. Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States. *JCO Oncology Practice*. 18(5):367-369, 2022.
- Hlubocky F, **Bosserman L**. Tribute to Dr. John Cox, 2021 Joseph V. Simone Awardee. *JCO Oncology Practice*. 18(8):e1231-e1233, 2022.
- Bosserman L**. Enhancing JCO Oncology Practice's Cancer Care Delivery and Quality Improvement Mission with Equity and Value Components. *JCO Oncology Practice*. 17(5):258-260, 2021.
- Bosserman L**. Enhancing Value Together Through JCO Oncology Practice. *JCO Oncology Practice*. 16(1):1-3, 2020.
- Patt D, Stella P, **Bosserman L**. Clinical Challenges and Opportunities with Current Electronic Health Records: Practicing Oncologists' Perspective. *Journal of Oncology Practice*. 14(10):577-579, 2018.
- Bosserman LD**. Benefits and Challenges of Growing Oncology Networks in the United States. *Journal of Oncology Practice*. 13(12):761-763, 2018.
- Tefferi A, Kantarjian H, **Bosserman LD**, et al. In Support of a Patient-Driven Initiative to Lower the High Price of Cancer Drugs. *Mayo Clinic Proceedings*. 90(8):996-1000, 2015.
- Bosserman LD*** Pathways, processes, team work: paving the way for value-based care. *Journal of Community and Supportive Oncology*. 14(7):287-290, 2016.
- Bosserman LD**. A call for action: leadership on quality, safety, and pay for performance in community oncology. *Community Oncology*. 2:351-355, 2005.
- Bosserman LD**. Delivering quality oncology care: the case for national treatment guidelines. *Community Oncology*. 2:51-52, 2005.

PUBLISHED ABSTRACTS & POSTER PRESENTATIONS **51** *selected*

- Taparra KA, **Bosserman LD**, Shah C, et al. Race and ethnicity reporting by US federal standards in high-impact phase 2/3 oncology clinical trial publications. *ASCO Annual Meeting*, 2023.
- Wong M, **Bosserman L**, Mortimer JE, et al. UGT1A1 *28/*28 genotype and risk of toxicity in breast cancer patients treated with sacituzumab govitecan. *ASCO Annual Meeting*, 2023.
- Bosserman LD**, Morse D, McNeese K, et al. Capturing discrete complete staging elements in EPIC for breast and prostate cancer: a QTP pilot. *ASCO Quality Symposia*, 2019.
- Denduluri N, **Bosserman LD**, et al. Risk of AML/MDS after adjuvant chemotherapy for early breast cancer. *ASCO Breast Cancer Symposium*, 2012. [Podium / General Session]
- Fizazi K, **Bosserman L**, et al. Denosumab Treatment of Prostate Cancer With Bone Metastases. *ESMO Annual Meeting*, 2008. [Oral Presentation]
- Bosserman LD**, et al. Development and Implementation of Effective Quality Guidelines in Community Cancer Centers. *ASCO Annual Meeting*, 2005.

SELECTED INVITED LECTURES & PRESENTATIONS

Estrogen, Testosterone & Progesterone in Women and Women with Breast Cancer: Understanding the Science, Myths and Gaps. Academic Summit, Bogotá, Colombia. *[Scheduled]* 11/2026

117 total — recent & representative shown; full list on request

Estrogen, Testosterone & Progesterone in Women and Women with Breast Cancer. Endocrine Society of Georgia Annual Meeting, Atlanta, GA. <i>[Scheduled]</i>	11/2026
Estrogen, Testosterone & Progesterone in Women and Women with Breast Cancer. World Link Academic Summit, Miami, FL. <i>[Scheduled]</i>	9/2026
Addressing Sexual Toxicities in Patients with Cancer: Second Annual Workshop. Annual MASCC Meeting, Melbourne, Australia.	6/2026
Hormone Therapy for Women with Hormone Positive Breast Cancer – Yes. RISE UP Breast Cancer Meeting, San Francisco, CA.	2/2026
Estrogen, Testosterone & Progesterone in Women and Women with Breast Cancer. COH Endocrinology Department, City of Hope, Duarte, CA.	11/2025
Addressing Sexual Toxicities in Patients with Cancer: First Annual Workshop. Annual MASCC Meeting, Seattle, WA.	6/2025
Using Technology and AI with Data Analytics to Empower Value-Based Oncology Care. Invited Panelist, South by Southwest Conference, Austin, TX.	3/2024
Sexual Health Issues in Patients with Cancer. Denali Oncology Group Annual Meeting, Sitka, AK.	2022
Elevating Global Oncology Capabilities through Direct Patient Services and Institutional Collaborations. City of Hope Global Oncology Symposium.	2022
Best Practices in Tele-Oncology. Memorial Sloan Kettering Annual NY Lung Cancer Symposia.	2020
Invited Keynote: Operationalizing Personalized Precision Oncology Care for Patients Everywhere. DNAnexus / ASHG Annual Meeting, Houston, TX.	2019
Invited Keynote: Engaging Precision Oncology to Deliver Value Based Medicine. CI4CC Spring Conference, La Jolla, CA.	2019
Pathways for Personalized Precision Medicine and Value: The City of Hope Experience. ASCO Quality Care Symposium, San Diego, CA.	2019
Invited Keynote: Beyond Pathways – Personalized Precision Oncology at the Bedside. CI4CC Fall Conference, New Orleans, LA.	2018
Keynote Address: How Oncology fits into Accountable Care Organizations. Duke University ASCO Update Symposium, Durham, NC.	2013
Invited Keynote: Using Community Based Networks to Improve Quality – the Future of Health Care. UCSF Cancer Symposia, San Francisco, CA.	2008

* Senior or Shared Senior Author / Curriculum Vitae updated May 2026